T. Rowe Price Investment Management, Inc. Crispr Therapeutics Ag Transaction History
T. Rowe Price Investment Management, Inc.
- $163 Billion
- Q1 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 2,704,331 shares of CRSP stock, worth $144 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
2,704,331
Previous 3,611,186
25.11%
Holding current value
$144 Million
Previous $226 Million
18.46%
% of portfolio
0.11%
Previous 0.15%
Shares
7 transactions
Others Institutions Holding CRSP
# of Institutions
550Shares Held
56.3MCall Options Held
2.91MPut Options Held
2.47M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.16MShares$433 Million3.97% of portfolio
-
Capital International Investors Los Angeles, CA7.84MShares$416 Million0.11% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.27MShares$174 Million0.16% of portfolio
-
Nikko Asset Management Americas, Inc.3.27MShares$174 Million2.23% of portfolio
-
Black Rock Inc. New York, NY2.55MShares$135 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.14B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....